Clinical Trial Detail

NCT ID NCT03916419
Title Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB and IIIA Non-small Cell Lung Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

lung non-small cell carcinoma

Therapies

Durvalumab

Carboplatin + Paclitaxel

Age Groups: adult senior

No variant requirements are available.